Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics (NASDAQ:NKTR) Stock Holdings Lessened by Advisors Asset Management Inc.
08:34am, Wednesday, 08'th Apr 2020
Advisors Asset Management Inc. trimmed its stake in Nektar Therapeutics (NASDAQ:NKTR) by 49.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commissio
Dublin, April 07, 2020 -- The "Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to.
Connor Clark & Lunn Investment Management Ltd. Takes Position in Nektar Therapeutics (NASDAQ:NKTR)
09:14am, Tuesday, 07'th Apr 2020
Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 25,675
8 Stocks You Can Count On During Any Crisis in 2020 | MarketBeat
12:00pm, Monday, 06'th Apr 2020
We’ve put together this presentation of eight stocks that you can count on during this crisis or any crisis.
Raymond James & Associates Increases Holdings in Nektar Therapeutics (NASDAQ:NKTR)
11:12am, Monday, 06'th Apr 2020
Raymond James & Associates grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commiss
Analysts Are Betting On Nektar Therapeutics (NASDAQ:NKTR) With A Big Upgrade This Week
10:28am, Monday, 06'th Apr 2020
Shareholders in Nektar Therapeutics (NASDAQ:NKTR) may be thrilled to learn that the analysts have just delivered a...
Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues
10:24am, Monday, 06'th Apr 2020
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Buy" by Analysts
10:00am, Monday, 06'th Apr 2020
Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the twenty brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst h
Cubist Systematic Strategies LLC Has $985,000 Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)
09:08am, Monday, 06'th Apr 2020
Cubist Systematic Strategies LLC raised its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 47.4% in the 4th quarter, according to the company in its most recent disclosure with the Securit
Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
06:55pm, Sunday, 05'th Apr 2020
Following up on its initial announcements in January and February, Incyte (NASDAQ:INCY) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2, evaluating a topica
Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)
12:21pm, Friday, 03'rd Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $18.00. The company's shares
Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)
12:21pm, Friday, 03'rd Apr 2020
Mizuho Securities analyst
Difei Yang
maintained a
Buy
rating on Xeris Pharmaceuticals (
XERS
–
Research Report
) today and set a price target of
$18.00
. The company’s shares closed last Thursday
Nektar Therapeutics (NASDAQ:NKTR) Lifted to "Neutral" at Goldman Sachs Group
10:26am, Friday, 03'rd Apr 2020
Goldman Sachs Group upgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a sell rating to a neutral rating in a report released on Monday, BenzingaRatingsTable reports. The firm currently has $20
First Republic Investment Management Inc. Sells 2,019 Shares of Nektar Therapeutics (NASDAQ:NKTR)
09:46am, Friday, 03'rd Apr 2020
First Republic Investment Management Inc. lessened its stake in Nektar Therapeutics (NASDAQ:NKTR) by 15.0% during the fourth quarter, according to its most recent filing with the Securities and Exchan
Nektar valuation unlikely to be hurt much by COVID-19, says Mizuho NKTR
11:43am, Thursday, 02'nd Apr 2020
Nektar valuation unlikely to be hurt much by COVID-19, says Mizuho Mizuho NKTR
